Anemia and the Low-risk MDS Patient: The Current Landscape and Future Directions

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: March 09, 2020
Expiration Date: March 09, 2021

Expected time to complete this activity as designed: 30 minutes

There are no fees for participating in or receiving credit for this online activity.

Program Overview

Anemia is the most common cytopenia in patients with lower-risk MDS. In this activity, Dr. Shyamala Navada describes this impact on outcomes and prognosis of patients while also identifying therapeutic strategies for treating anemia which aim to reduce transfusion burden. She will also review the investigational agents currently in clinical development that are likely to provide new options for lower-risk MDS.

Target Audience

This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, pharmacists and other allied healthcare professionals who provide care to patients with myelodysplastic syndromes.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Describe the potential impact of anemia on outcomes and prognoses of patients with low-risk MDS
  • Identify currently available and emerging therapeutic strategies for treating anemia in patients with low-risk MDS
  • Outline practical clinical strategies for the effective management of anemia in optimized therapeutic regimens for patients with low-risk MDS


Anemia and the Low-risk MDS Patient: The Current Landscape and Future Directions – Shyamala C. Navada, MD, MSCR

Instructions for Participation and Credit

This activity is eligible for credit through March 09, 2021. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biography

Shyamala C. Navada, MD, MSCR
Assistant Professor
Mount Sinai School of Medicine
Department of Medicine
Division of Hematology/Oncology
New York, New York

Dr. Shyamala Navada received her medical degree from the University of Illinois College of Medicine in Chicago, as well as a master’s of science in clinical research from Mount Sinai School of Medicine in New York City. She completed a medical residency at the University of Michigan Hospitals and a hematology/oncology fellowship at Mount Sinai School of Medicine. Dr. Navada is Assistant Professor at Mount Sinai School of Medicine, Department of Medicine, Division of Hematology/Oncology, she is also an Assistant Attending Physician at Mount Sinai Beth Israel.

Dr. Navada is board certified in hematology and medical oncology. Her academic career in clinical and translational research in myelodysplastic syndromes (MDS) focuses on designing early phase trials investigating the role of novel candidate drugs to improve the outcome of patients with MDS and acute myeloid leukemia (AML). Her clinical expertise is in the medical management of MDS and AML, and she also manages patients with benign hematologic conditions, such as cytopenias. As a result of her academic and research activities, Dr. Navada has presented at national and international meetings, including the American Society of Hematology, International Bone Marrow Failure Disease Scientific Symposium, International Symposium on Myelodysplastic Syndromes, and the European Hematology Association Congress. In addition, she is the author/co-author of medical textbook chapters and articles in peer-reviewed journals, including The Journal of Clinical Investigation and Leukemia Research.


Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.5 contact hours of Continuing Education Credit.
Universal Activity Number: 827-0000-20-009-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.

International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.


As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosure

Dr. Shyamala Navada has received grant support related to research activities from Onconova Therapeutics.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Andrea Mathis, Project Manager, and Joan Meyer, RN, MHA, Executive Director, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Astex Pharmaceuticals, Celgene Corporation, and Takeda Oncology.

©2020 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.